Company: CERO
Filing Date: 2025-07-21
Form Type: S-1
Source: 0001213900-25-066152
Chunk: 344

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-21
Form: S-1
Chunk 344
---
 yield  |     |            |      - | % |
| Expected volatility      |     |            | 121.09 | % |

For the period from February 14, 2024 through March 31, 2024,
the Company recorded stock-based compensation expense of $ million, of which $ million was related to R&D and $ million
was related to general and administrative. For the period from January 1, 2024 through February 13, 2024, Predecessor recorded an immaterial
amount of stock-based compensation expense.

For the three months ended
March 31, 2025, the Company recorded stock-based compensation expense of $, of which $ was related to research and development
and $ was related to general and administrative.

As of March 31, 2025, the Company had approximately $ of unamortized
stock-based compensation expense related to unvested stock options, which is expected to be recognized over a weighted average period
of years. The weighted average grant date calculated fair value per share of the Company’s options granted during the three
months ended March 31, 2025 was $. The weighted average grant date calculated fair value per share of the Company’s options
granted during the period February 14, 2024, through March 31, 2024, was $.

NOTE 12 – 401(K) RETIREMENT SAVINGS PLAN The Company sponsors a 401(k) defined contribution plan covering eligible employees who elect to participate. The Company is allowed to make discretionary profit sharing and 401(k) matching contributions as defined in the plan and as approved by the Board of Directors. The Company’s contributions for the period from February 14, 2024 through March 31, 2024 was $ 7,956and Predecessor contributions during the period from January 1, 2024 through February 13, 2024 was $ 4,685. The Company did not make any contributions to the 401(k) during the three months ended March 31, 2025.

NOTE 13 – RELATED-PARTY TRANSACTIONS

In February 2024, we issued
and sold an aggregate of shares of Series A Preferred Stock, Series A Common Warrants and Preferred Warrants, at a price
of $ per share of Series A Preferred Stock, for aggregate cash proceeds of approximately $ million, plus additional cash proceeds
of up to $ million if the Preferred Warrants are exercised.

The